Evidence map›Paper›PMID 36015075›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Design, Synthesis, and Development of Pyrazolo[1,5-

Mariola Stypik, Stanisław Michałek, Nina Orłowska, Marcin Zagozda, Maciej Dziachan, Martyna Banach, Paweł Turowski, Paweł Gunerka, Daria Zdżalik-Bielecka, Aleksandra Stańczak and 13 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Tuning the Biological Activity of PI3KMolecules (Basel, Switzerland) · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Mariola StypikCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0002-4200-868X
Stanisław MichałekCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0002-6648-0604
Nina OrłowskaCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Marcin ZagozdaCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Maciej DziachanCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Martyna BanachCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Paweł TurowskiCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Paweł GunerkaCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0003-0239-208X
Daria Zdżalik-BieleckaCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0003-3096-8293
Aleksandra StańczakCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Urszula KędzierskaCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Krzysztof MulewskiCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Damian SmugaCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Wioleta MaruszakCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Lidia Gurba-BryśkiewiczCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0002-7807-6641
Arkadiusz LeniakCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0002-4462-4603
Wojciech PietruśCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0002-8563-7929
Zbigniew OchalFaculty of Chemistry, Warsaw University of Technology, ul. Noakowskiego 3, 00-664 Warsaw, Poland.
Mateusz MachCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.ORCID 0000-0003-2560-9587
Beata ZygmuntCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Jerzy PieczykolanCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Krzysztof DubielCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Maciej WieczorekCelon Pharma S.A., ul. Marymoncka 15, 05-152 Kazun Nowy, Poland.
Celon Pharma (Poland) · PLWarsaw University of Technology · PL

Funding

The National Centre for Research and Development POIR.01.01.01-00-1341/15
6 · The paper itself

Abstract

Phosphoinositide 3-kinase (PI3K) is the family of lipid kinases participating in vital cellular processes such as cell proliferation, growth, migration, or cytokines production. Due to the high expression of these proteins in many human cells and their involvement in metabolism regulation, normal embryogenesis, or maintaining glucose homeostasis, the inhibition of PI3K (especially the first class which contains four subunits:

Indexed as

5-benzimidazole-pyrazolo[1,5-a]pyrimidineanti-inflammatory therapyCPL302415PI3Kδ inhibitors

Identifiers

PMID36015075
PMCPMC9415947
OpenAlexW4288448370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.